![Yoshihiro Otaki](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Yoshihiro Otaki
President chez BioFrontier Partners, Inc.
Postes actifs de Yoshihiro Otaki
Sociétés | Poste | Début | Fin |
---|---|---|---|
BioFrontier Partners, Inc.
![]() BioFrontier Partners, Inc. Investment ManagersFinance BioFrontier Partners Inc (BioFrontier Partners) is a venture capital firm founded in 2000. The firm is headquartered in Tokyo, Japan. | President | 10/03/1999 | - |
GeneCare Research Institute Co., Ltd.
![]() GeneCare Research Institute Co., Ltd. Medical/Nursing ServicesHealth Services GeneCare Research Institute Co., Ltd. engages in the research, development, and drug discovery of treatments in the field of cancer, inflammation, hepatic carcinoma and rheumatism. It provides the distribution services for its products through their direct customers, which includes pharmaceutical companies and clinical-related companies. The company was founded by Yasuhiro Furuichi on December 20, 2000 and is headquartered in Kamakura, Japan. | Directeur/Membre du Conseil | 20/12/2000 | - |
Healthcare Innovation Co. Ltd.
![]() Healthcare Innovation Co. Ltd. Investment ManagersFinance Healthcare Innovation Co. Ltd. (Healthcare Innovation) is a Venture Capital firm founded in 2017. The firm is headquartered in Tokyo, Japan. | Président | - | - |
Cell-Medicine, Inc.
![]() Cell-Medicine, Inc. Pharmaceuticals: MajorHealth Technology Cell-Medicine, Inc. is a Japanese company that specializes in cancer immunotherapy based on scientific evidence. The private company is based in Tsukuba, Japan. The company aims to prevent the recurrence of cancer after surgery, prevent metastasis, and treat remaining cancer. The company's self-cancer vaccine therapy is based on scientific evidence and is designed to target recurring and metastasizing cancer after surgery, as well as treat remaining cancer. The company was founded in 2001 by Tadao Ono. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Yoshihiro Otaki
Anciens postes connus de Yoshihiro Otaki
Sociétés | Poste | Début | Fin |
---|---|---|---|
HUMAN METABOLOME TECHNOLOGIES, INC. | Président | 01/07/2003 | - |
Fondateur | 01/07/2003 | - |
Formation de Yoshihiro Otaki
Tohoku University | Doctorate Degree |
Statistiques
Internationale
Japon | 7 |
Opérationnelle
Chairman | 2 |
Director/Board Member | 2 |
President | 1 |
Sectorielle
Finance | 3 |
Health Technology | 3 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
HUMAN METABOLOME TECHNOLOGIES, INC. | Health Technology |
Entreprise privées | 4 |
---|---|
BioFrontier Partners, Inc.
![]() BioFrontier Partners, Inc. Investment ManagersFinance BioFrontier Partners Inc (BioFrontier Partners) is a venture capital firm founded in 2000. The firm is headquartered in Tokyo, Japan. | Finance |
GeneCare Research Institute Co., Ltd.
![]() GeneCare Research Institute Co., Ltd. Medical/Nursing ServicesHealth Services GeneCare Research Institute Co., Ltd. engages in the research, development, and drug discovery of treatments in the field of cancer, inflammation, hepatic carcinoma and rheumatism. It provides the distribution services for its products through their direct customers, which includes pharmaceutical companies and clinical-related companies. The company was founded by Yasuhiro Furuichi on December 20, 2000 and is headquartered in Kamakura, Japan. | Health Services |
Healthcare Innovation Co. Ltd.
![]() Healthcare Innovation Co. Ltd. Investment ManagersFinance Healthcare Innovation Co. Ltd. (Healthcare Innovation) is a Venture Capital firm founded in 2017. The firm is headquartered in Tokyo, Japan. | Finance |
Cell-Medicine, Inc.
![]() Cell-Medicine, Inc. Pharmaceuticals: MajorHealth Technology Cell-Medicine, Inc. is a Japanese company that specializes in cancer immunotherapy based on scientific evidence. The private company is based in Tsukuba, Japan. The company aims to prevent the recurrence of cancer after surgery, prevent metastasis, and treat remaining cancer. The company's self-cancer vaccine therapy is based on scientific evidence and is designed to target recurring and metastasizing cancer after surgery, as well as treat remaining cancer. The company was founded in 2001 by Tadao Ono. | Health Technology |
- Bourse
- Insiders
- Yoshihiro Otaki
- Expérience